2024
Nanotechnology approaches to drug delivery for the treatment of ischemic stroke
Peng B, Mohammed F, Tang X, Liu J, Sheth K, Zhou J. Nanotechnology approaches to drug delivery for the treatment of ischemic stroke. Bioactive Materials 2024, 43: 145-161. PMID: 39386225, PMCID: PMC11462157, DOI: 10.1016/j.bioactmat.2024.09.016.Peer-Reviewed Original ResearchBlood-brain barrierClinical translationClinical trialsFDA-approved pharmacotherapiesReview therapeutic agentsIschemic strokeTherapeutic agentsEffective treatment optionDrug deliveryTreatment of ischemic strokePotential clinical translationGlobal public health concernImprove delivery efficiencyTreatment optionsTreatment strategiesIschemic brainPublic health concernStroke pharmacotherapyEngineered nanoparticlesStroke treatment strategiesDelivery efficiencyNanotechnological approachesDrugPharmacotherapyStrokeAPOE epsilon variants and composite risk of dementia, disability, and death in the health and retirement study
Clocchiatti‐Tuozzo S, Szejko N, Rivier C, Renedo D, Huo S, Sheth K, Gill T, Falcone G. APOE epsilon variants and composite risk of dementia, disability, and death in the health and retirement study. Journal Of The American Geriatrics Society 2024, 72: 2989-2999. PMID: 38946154, PMCID: PMC11461103, DOI: 10.1111/jgs.19043.Peer-Reviewed Original ResearchRisk of dementiaOutcome of dementiaAssociated with lower riskOlder adultsRetirement StudySecondary analysisEffects of tested interventionsHealth and Retirement StudyClinical trials of older adultsApo E4Composite outcomePrimary analysisHigh riskLow riskCox proportional hazards modelsProportional hazards modelMultivariate Cox proportional hazards modelDementiaAPOE genotypeClinical trialsHazards modelDisabilityParticipantsFunctional outcomesHeart disease
2023
Intensive Blood Pressure Reduction is Associated with Reduced Hematoma Growth in Fast Bleeding Intracerebral Hemorrhage
Li Q, Morotti A, Warren A, Qureshi A, Dowlatshahi D, Falcone G, Sheth K, Shoamanesh A, Murthy S, Viswanathan A, Goldstein J. Intensive Blood Pressure Reduction is Associated with Reduced Hematoma Growth in Fast Bleeding Intracerebral Hemorrhage. Annals Of Neurology 2023, 95: 129-136. PMID: 37706569, DOI: 10.1002/ana.26795.Peer-Reviewed Original ResearchBlood pressure reductionIntensive Blood Pressure ReductionIntensive BP reductionIntracerebral hemorrhageHematoma growthBP reductionPressure reductionImproved functional independenceIntensive BP loweringLarge clinical trialsSpontaneous intracerebral hemorrhageAntihypertensive treatmentHemorrhage 2BP loweringSymptom onsetHematoma volumeHematoma expansionClinical trialsHigh riskTomography timePatientsFunctional independenceEarly useHemorrhageLower ratesRadiomic markers of intracerebral hemorrhage expansion on non-contrast CT: independent validation and comparison with visual markers
Haider S, Qureshi A, Jain A, Tharmaseelan H, Berson E, Zeevi T, Werring D, Gross M, Mak A, Malhotra A, Sansing L, Falcone G, Sheth K, Payabvash S. Radiomic markers of intracerebral hemorrhage expansion on non-contrast CT: independent validation and comparison with visual markers. Frontiers In Neuroscience 2023, 17: 1225342. PMID: 37655013, PMCID: PMC10467422, DOI: 10.3389/fnins.2023.1225342.Peer-Reviewed Original ResearchIndependent validation cohortIntracerebral hemorrhageRadiomic featuresValidation cohortClinical variablesHematoma expansionSpontaneous supratentorial intracerebral hemorrhageNon-contrast head CTSupratentorial intracerebral hemorrhageTomography (CT) of patientsNon-contrast headFuture clinical trialsNon-contrast CTIntracerebral Hemorrhage ExpansionHigh predictive valueBAT scoreHypertensive patientsClinical predictorsPrognostic relevanceFunctional outcomeClinical trialsHead CTHemorrhage expansionClinical trial datasetDiscovery cohort
2022
Nanoparticle-based drug delivery for the treatment of traumatic brain injury
Mohammed F, Omay S, Sheth K, Zhou J. Nanoparticle-based drug delivery for the treatment of traumatic brain injury. Expert Opinion On Drug Delivery 2022, 20: 55-73. PMID: 36420918, PMCID: PMC9983310, DOI: 10.1080/17425247.2023.2152001.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryBrain injurySecondary outcomesClinical trialsPathophysiology of TBIPhase III clinical trialsPhase II clinical trialClinical management strategiesSite of injuryOff-target toxicityPharmacological treatmentBrain penetrationLow off-target toxicityExperimental animalsInjuryChronic timescalesDosage thresholdDrug deliveryTrialsDrug targetingOutcomesTreatmentDeliveryPathophysiologyThe Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results
Lyden PD, Bosetti F, Diniz MA, Rogatko A, Koenig JI, Lamb J, Nagarkatti KA, Cabeen RP, Hess DC, Kamat PK, Khan MB, Wood K, Dhandapani K, Arbab AS, Leira EC, Chauhan AK, Dhanesha N, Patel RB, Kumskova M, Thedens D, Morais A, Imai T, Qin T, Ayata C, Boisserand LSB, Herman AL, Beatty HE, Velazquez SE, Diaz-Perez S, Sanganahalli BG, Mihailovic JM, Hyder F, Sansing LH, Koehler RC, Lannon S, Shi Y, Karuppagounder SS, Bibic A, Akhter K, Aronowski J, McCullough LD, Chauhan A, Goh A, Siddiqui S, Sheth K, Matouk C, Cruz C, Zhou J, Dawson V, Dawson T, Liang J, van Zijl P, Zeiler S, Taylor Kimberly W, Erdogan T, Yu L, Mandeville J, Whittier J. The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results. Stroke 2022, 53: 1802-1812. PMID: 35354299, PMCID: PMC9038686, DOI: 10.1161/strokeaha.121.038047.Peer-Reviewed Original ResearchConceptsPreclinical assessmentStroke treatmentCandidate treatmentMiddle cerebral artery occlusion (MCAO) surgeryClinical stroke trialsSuccessful stroke treatmentInclusion/exclusion criteriaStroke clinical trialsClinical trial designYoung male animalsComorbid diseasesOcclusion surgeryCerebral ischemiaNeurological disabilityComorbid conditionsStroke trialsProtocol adherenceBlinded assessmentSuch therapyClinical trialsClinical studiesExclusion criteriaTrial designAged animalsOutcome assessment
2021
Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group
Garcia M, Johnson S, Bosch N, Sisson E, Sheldrick C, Kumar V, Boman K, Bolesta S, Bansal V, Deo N, Domecq J, Lal A, Christie A, Banner-Goodspeed V, Sanghavi D, Vadgaonkar G, Gajic O, Kashyap R, Walkey A, Mesland J, Henin P, Petre H, Buelens I, Gerard A, Clevenbergh P, Markotić D, Bošnjak I, Garza R, Chu E, Chan V, Gavidia O, Pachon F, Sanchez Y, Kassas M, Badr M, Tawheed A, Tawheed A, Yahia H, Coello J, Perez G, Lizardo A, Guillen G, Soto H, Segu S, Chakraborty T, Joyce E, Vadgaonkar G, Ediga R, Basety S, Dammareddy S, Kasumalla P, Raju U, Manduva J, Kolakani N, Sripathi S, Chaitanya S, Daga M, Agarwal M, Rohtagi I, Papani S, Kamuram M, Agrawal K, Baghel V, Patel K, Mohan S, Jyothisree E, Matsuda W, Suzuki R, Kyo M, Itagaki Y, Kodate A, Suzuki R, Kodate A, Takahashi Y, Moriki K, Hassan-Hanga F, Galadanci H, Gezawa A, Kabara H, Amole T, Kabir H, Haliru D, Ibrahim A, Asghar M, Syed M, Naqvi S, Zabolotskikh I, Zybin K, Sinkov S, Musaeva T, Almazyad M, Alarifi M, Macarambon J, Bukhari A, Albahrani H, Asfina K, Aldossary K, Zdravkovic M, Todorovic Z, Popadic V, Klasnja S, Kovacevic B, Bojicic J, Stevanovic P, Stojakov D, Ignjatovic D, Bojic S, Bobos M, Nenadic I, Zaric M, Djuric M, Djukic V, Teruel S, Martin B, Teruel S, Sili U, Bilgin H, Ay P, Raval A, Franks A, Kharbanda A, Jhajhria S, Fyffe Z, Capizzi S, Alicie B, Green M, Crockarell L, Drennan A, Dubuque K, Fambrough T, Gasaway N, Krantz B, Nebi P, Orga J, Serfass M, Simion A, Warren K, Wheeler C, Woolman C, Christie A, Ashley D, Adiga R, Moyer A, Verghese G, Newsome A, Forehand C, Bruning R, Jones T, Sabov M, Zaidi F, Tissavirasingham F, Malipeddi D, Armaignac D, Parris D, Zuniga M, Vargas I, Boronat V, Hutton A, Kaur N, Neupane P, Sadule-Rios N, Rojas L, Neupane A, Rivera P, Carlos C, Vincent G, Banner-Goodspeed V, Bose S, Kelly L, Joseph M, McGourty M, Capers K, Hoenig B, Karamourtopoulos M, Law A, Kassis E, Walkey A, Waikar S, Garcia M, Colona M, Kibbelaar Z, Leong M, Wallman D, Soni K, Maccarone J, Gilman J, Devis Y, Chung J, Paracha M, Lumelsky D, DiLorenzo M, Abdurrahman N, Johnson S, Zammit K, Patrick J, Loeffler W, Maya R, Tirupathi R, Tang A, Safi A, Green C, Newell J, Gist K, Sayed I, Brinton J, Strom L, Daugherty S, Atkinson S, Shrimpton K, Yamane D, Benjenk I, Prasanna N, Smalls N, Smith M, Snow W, Liptak R, Durant H, Pendleton V, Nanavati A, Mrozowsk R, Liu Y, Zavala S, Zavala S, Shim E, Reilkoff R, Heneghan J, Eichen S, Goertzen L, Rajala S, Feussom G, Tang B, Junia C, Lichtenberg R, Sidhu H, Espinoza D, Rodrigues S, Zabala M, Goyes D, Susheela A, Hatharaliyadda B, Rameshkumar N, Kasireddy A, Maldonado G, Beltran L, Chaugule A, Khan H, Cartin-Ceba R, Sen A, Palacios A, Mahdi G, Kashyap R, Gajic O, Bansal V, Tekin A, Lal A, O’Horo J, Deo N, Sharma M, Qamar S, Domecq J, Singh R, Niven A, La Nou A, Bogojevic M, Mullen B, Sanghavi D, Franco P, Guru P, Gnanapandithan K, Saunders H, Fleissner Z, Garcia J, Yu A, Mateus L, Yarrarapu S, Kaur N, Giri A, Khan S, Domecq J, Jain N, Koritala T, Timmer J, Welker K, Venkata C, Engemann M, Mantese A, Eschler A, Hejna M, Lewandowski E, Kusmierski K, Martin C, Aulakh B, Tripathi S, Bandy J, Kreps L, Bollinger D, Stienecker R, Melendez A, Brunner T, Budzon S, Heffernan J, Souder J, Miller T, Maisonneuve A, Delmonaco B, Franklin A, Heath M, Vilella A, Kutner S, Clark K, Moore D, Anderson I, Rajkumar D, Abunayla A, Heiter J, Zaren H, Smith S, Lewis G, Seames L, Farlow C, Miller J, Broadstreet G, Martinez A, Allison M, Mittal A, Ruiz R, Skaanland A, Ross R, Mohabir P, O’Brien C, Dasani K, Gupta N, Jones T, Ayers S, Harrell A, Brown B, Edwards M, Darby C, Page K, Brown A, McAbee J, Belden K, Baram M, Weber D, DePaola R, Xia Y, Carter H, Tolley A, Barletta M, Ferranti M, Sines B, Bice T, McGonagill P, Galet C, Hubbard J, Wang D, Allan L, Badheka A, Chegondi M, Nazir U, Rampon G, Riggle J, Dismang N, Alvarez R, Alarcon-Calderon A, Sosa M, Mahabir S, Patel M, Dandachi D, Regunath H, Camazine M, Geiger G, Njai A, Saad B, Stapleton R, Dixon A, Johnson O, Ardren S, Burns S, Raymond A, Gonyaw E, Hodgdon K, Housenger C, Lin B, McQuesten K, Pecott-Grimm H, Sweet J, Ventrone S, Khanna A, Harris L, Cusson B, Fowler J, Vaneenenaam D, McKinney G, Udoh I, Johnson K, Pattan V, Papke J, Jimada I, Mhid N, Chakola S, Sheth K, Ammar A, Ammar M, Lopez V, Dela Cruz C, Khosla A, Gautam S. Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. Critical Care Explorations 2021, 3: e0566. PMID: 34746796, PMCID: PMC8565794, DOI: 10.1097/cce.0000000000000566.Peer-Reviewed Original ResearchTherapeutic dose anticoagulantsCoronavirus disease 2019Disease 2019Hospital variationClinical trialsViral infectionClinical trial evidenceObservational cohort studyUse of hydroxychloroquineRandomized clinical trialsRisk-adjusted mortalityUse of antiviralsCoronavirus disease 2019 (COVID-19) pandemicRisk-adjusted variationRandom effects logistic regression modelDisease 2019 pandemicEffects logistic regression modelsLogistic regression modelsCohort studyMedication useTrial evidenceEvidence-based practiceInternational HospitalMAIN OUTCOMEMedicationsTop Priorities for Cerebroprotective Studies—A Paradigm Shift
Lyden P, Buchan A, Boltze J, Fisher M, Ansari S, Broderick J, Campbell B, Chaisinanunkul N, Chen C, Grotta J, Haddad W, Hareedy R, Hill M, Houser G, Jadhav A, Khatri P, Kimberly W, Koenig J, Korinek W, Landen J, Lansberg M, Latour L, Liebeskind D, Liston T, Lynch J, McGonigle J, Mistry E, Mocco J, Pryor K, Saver J, Savitz S, Sheth K, Solberg Y, Vagal A, Venkatasubramanian C, Ziogas N. Top Priorities for Cerebroprotective Studies—A Paradigm Shift. Stroke 2021, 52: 3063-3071. PMID: 34289707, PMCID: PMC8384700, DOI: 10.1161/strokeaha.121.034947.Peer-Reviewed Original ResearchConceptsComprehensive preclinical assessmentPreclinical assessmentNeurovascular unitMajor public health concernSalvageable brain tissueStroke symptom onsetIschemic stroke treatmentBlood-brain barrierConsensus-based recommendationsPharmacokinetics/pharmacodynamicsClinical trial designPaucity of evidencePublic health concernDifferent brain regionsMechanism of actionCerebroprotective agentTerm neuroprotectionIschemic strokeSymptom onsetStroke treatmentClinical outcomesComorbid conditionsCore injuryClinical trialsStroke modelAcute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice
Campbell B, Lansberg M, Broderick J, Derdeyn C, Khatri P, Sarraj A, Saver J, Vagal A, Albers G, Adeoye O, Ansari S, Boltze J, Buchan A, Chaisinanunkul N, Chen C, Davis T, Ermakova T, Fisher M, Haddad W, Hill M, Houser G, Jadhav A, Kimberly W, Landen J, Liebeskind D, Lyden P, Lynch J, Mansi C, Mocco J, Nogueira R, Savitz S, Schwamm L, Sheth K, Solberg Y, Venkatasubramanian C, Warach S, Wechsler L, Zhu B, Ziogas N. Acute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice. Stroke 2021, 52: 2723-2733. PMID: 34233464, PMCID: PMC8316368, DOI: 10.1161/strokeaha.121.035132.Peer-Reviewed Original ResearchConceptsPrimary stroke centerAcute stroke clinical trialsStroke centersStroke clinical trialsReperfusion therapyClinical trialsConsensus recommendationsComprehensive stroke centerAcute stroke trialsImaging sessionOptimal imaging strategyExtended time windowStroke neurologistsAcute strokeStroke trialsImaging selectionComputed tomographyTreatment windowUS FoodDrug AdministrationNeurological disordersStroke imagingTrialsNational InstituteOptimal imaging
2013
Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke
Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ. Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke. Stroke 2013, 45: 281-283. PMID: 24193798, PMCID: PMC4235339, DOI: 10.1161/strokeaha.113.003352.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBrain EdemaBrain IschemiaComorbidityFemaleFibrinolytic AgentsGlyburideHumansHypoglycemiaHypoglycemic AgentsInjections, IntravenousMagnetic Resonance ImagingMaleMiddle AgedPatient SafetyPilot ProjectsProspective StudiesStrokeTissue Plasminogen ActivatorTreatment OutcomeWhite PeopleYoung AdultConceptsIschemic strokeLesion volumeIntravenous recombinant tissue-type plasminogen activatorRecombinant tissue-type plasminogen activatorIpsilateral hemisphere volumeLarge ischemic strokeSerious adverse eventsAcute ischemic strokeRetrospective clinical dataFeasibility of recruitingTissue-type plasminogen activatorIntravenous glyburideSevere strokeSymptomatic hypoglycemiaAdverse eventsFocal ischemiaMean ageClinical trialsHemisphere volumeClinical dataDose reductionAge 18PatientsSulfonylurea receptorPlasminogen activator